YaoGeJu

Company directoryChina company filings

Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 8542cfffdf

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

23 acceptance records as first applicant, grouped into 15 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

对乙酰氨基酚甘露醇注射液 · No verified English name 1 records · Latest accepted 2026/06/18

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601450Generic2026/06/18Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Dong Guan Shi Pu Ji Pharma Co., Ltd. romanizedCDE ↗
头孢呋辛酯分散片 · No verified English name 2 records · Latest accepted 2025/07/24

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2501475Supplement2025/07/24Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2140512Supplement2021/06/25Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
盐酸左沙丁胺醇雾化吸入溶液 · No verified English name 2 records · Latest accepted 2025/06/18

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502188Generic2025/06/18Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2404181Generic2024/12/04Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Memantine Hydrochloride Sustained-release Capsules 2 records · Latest accepted 2025/05/13

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500953Supplement2025/05/13Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Li Pin Pharma (Xiamen) Co., Ltd. romanizedCDE ↗
CYHB2500952Supplement2025/05/13Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Li Pin Pharma (Xiamen) Co., Ltd. romanizedCDE ↗
环丙沙星缓释片 · No verified English name 1 records · Latest accepted 2024/09/15

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2401497Supplement2024/09/15Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension 2 records · Latest accepted 2024/05/22

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2400685Supplement2024/05/22Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedCDE ↗
CYHS2101059Generic2021/04/14Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Beijing Bai Ao Pharma Co., Ltd. romanizedCDE ↗
辛伐他汀分散片 · No verified English name 3 records · Latest accepted 2023/11/15

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2350831Supplement2023/11/15Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2350830Supplement2023/11/15Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2350829Supplement2023/11/15Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Atorvastatin Calcium Tablets 1 records · Latest accepted 2023/10/24

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2340017Supplement2023/10/24Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Ibuprofen Suspension 1 records · Latest accepted 2023/05/27

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301218Supplement2023/05/27Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Jilin Yi Min Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
帕拉米韦氯化钠注射液 · No verified English name 2 records · Latest accepted 2023/05/24

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301199Supplement2023/05/24Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2301198Supplement2023/05/24Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
布洛芬混悬滴剂 · No verified English name 1 records · Latest accepted 2023/03/31

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300654Supplement2023/03/31Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Jilin Yi Min Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
Ciprofloxacin Lactate and Sodium Chloride Injection 2 records · Latest accepted 2023/02/21

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300357Supplement2023/02/21Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2300356Supplement2023/02/21Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Fexofenadine Hydrochloride Oral Suspension 1 records · Latest accepted 2023/02/03

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300319Generic2023/02/03Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Hunan Jiudian Pharmaceutical Co., LtdCDE ↗
头孢泊肟酯干混悬剂 · No verified English name 1 records · Latest accepted 2022/10/21

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2250654Supplement2022/10/21Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗
Benazepril Hydrochloride and Hydrochlorothiazide Tablets 1 records · Latest accepted 2021/04/01

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2140502Supplement2021/04/01Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
对乙酰氨基酚甘露醇注射液 · No verified English name CYHS2601450Generic2026/06/18Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanized; Dong Guan Shi Pu Ji Pharma Co., Ltd. romanizedCDE ↗
盐酸左沙丁胺醇雾化吸入溶液 · No verified English name CYHS2502188Generic2025/06/18Guangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedCDE ↗

Catalogue holder records

8 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
头孢泊肟酯干混悬剂 · No verified English nameGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H200801792024/08/23Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Atorvastatin Calcium TabletsGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H202271422024/04/17Drug that passed quality-and-efficacy consistency evaluationCDE ↗
头孢呋辛酯分散片 · No verified English nameGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H200308542023/07/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Oseltamivir Phosphate For Oral SuspensionGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedBo Rui Pharmaceutical (Suzhou) Co., Ltd. romanized国药准字H202336232023/05/29Generic approved under the new chemical-drug registration classificationCDE ↗
Benazepril Hydrochloride and Hydrochlorothiazide TabletsGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H200900042023/02/10Drug that passed quality-and-efficacy consistency evaluationCDE ↗
头孢克洛干混悬剂 · No verified English nameGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H200454322022/01/26Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Ciprofloxacin Lactate and Sodium Chloride InjectionGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H200230502021/11/11Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Ciprofloxacin Lactate and Sodium Chloride InjectionGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanizedGuangzhou Nan Xin Pharmaceutical Co., Ltd. romanized国药准字H440201062021/11/11Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.